Matinas BioPharma Reports 2017 Second Quarter Financial Results And Reaffirms Clinical And Regulatory Strategy To Advance MAT2203 And MAT2501

BEDMINSTER, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced its financial results for the quarter ended June 30, 2017 and reviewed the operational progress of its lead anti-infective products in development and expected near-term milestones. As previously announced, the Company will host a business update conference call with live audio webcast today, August 8th at 8:30 AM ET (details below).